ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

Research Progress and Clinical Translation Prospects of Stem Cell Technology in Regenerative Medicine

Yuxin Li[1,2,*], Zhongqian Wu[1], Na Lu[1], Jie Xu[1]

[1]*School of Management & Engineering, Nanjing University, Nanjing, 210093, Jiangsu, China*
[2]*Jiangsu Key Laboratory of Digital Finance, Suzhou, 215133, Jiangsu, China*
[*]*Corresponding author*

Abstract: *As a cutting-edge discipline for solving tissue and organ damage repair and difficult disease treatment, the development of regenerative medicine highly relies on breakthroughs and transformations in stem cell technology. This article systematically reviews the research progress and clinical translation status of stem cell technology in the field of regenerative medicine, with a focus on analyzing the biological characteristics and application advantages of major cell types such as mesenchymal stem cells and induced pluripotent stem cells. It explores the innovative fusion achievements of key technologies such as directed differentiation, 3D bioprinting, and cell-free therapy. Research has shown that stem cell technology has made significant breakthroughs in the clinical translation of neurodegenerative diseases, metabolic diseases, cardiovascular diseases, and other fields. However, it still faces core challenges such as insufficient technical standardization, safety risk management, ethical regulatory adaptation, and broken industrial transformation chains. In the future, by promoting the precise and multidisciplinary integration of stem cell technology, improving the collaborative innovation system and standardized regulatory mechanism of "industry university research application", we can effectively break through the barriers to transformation. The research conclusion of this article provides theoretical reference for the high-quality development of stem cell technology in the field of regenerative medicine, helping it achieve a leap from laboratory research to large-scale clinical application, and providing revolutionary solutions for the treatment of difficult diseases.*

Keywords: *stem cells; regenerative medicine; clinical translation; mesenchymal stem cell; cell free therapy*

1. Introduction

Regenerative medicine, as a cutting-edge interdisciplinary field in biomedicine, focuses on tissue and organ repair and functional reconstruction, aiming to break through the limitations of traditional medicine in treating difficult diseases such as degenerative diseases and severe injuries, and meet the urgent clinical needs of the global aging population [1]. Stem cell technology, with its self-renewal and multi-directional differentiation characteristics, provides core "seed cells" support for regenerative medicine, becoming a key bridge connecting basic research and clinical applications. Its level of development directly determines the breakthrough height of regenerative medicine [2].

Stem cells can be divided into embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs) according to their sources. The pluripotency potential of embryonic stem cells is significant but limited by ethical and immune rejection; Adult stem cells (such as mesenchymal stem cells) have a wide range of sources and high safety, and have shown good repair effects; IPSC has become a research hotspot due to its ability to avoid ethical controversies and possess personalized advantages [3]. Currently, breakthroughs in key technologies such as directed differentiation and cell delivery have laid the foundation for clinical translation.

Internationally, the United States, Europe, and other countries have promoted the clinical and even market launch of multiple stem cell therapies through improved regulatory and funding mechanisms, and trials of iPSC derived cell therapy for neurodegenerative diseases have made progress. With the introduction of relevant policies and the gradual improvement of the regulatory system in China, local teams have obtained independent intellectual property achievements in areas such as large-scale preparation, and have promoted the filing of multiple clinical studies [4]. However, clinical translation still faces bottlenecks such as insufficient standardization, low delivery efficiency, and long-term safety

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

risks. The deficiencies in ethical supervision and industry university research collaboration also constrain the industrialization process [5].

This article systematically reviews the progress and technological breakthroughs in stem cell research, analyzes the current status and cases of clinical translation, explores core challenges, and looks forward to development prospects. The aim is to clarify the collaborative logic between the two, provide theoretical references for technology translation and industrialization, and assist in the high-quality development of regenerative medicine.

2. Research progress of stem cell technology in regenerative medicine

2.1 Research breakthroughs in different types of stem cells

Stem cells from different sources have shown different application advantages and research directions in regenerative medicine due to their biological characteristics. In recent years, key breakthroughs have been achieved in the research of various types of stem cells. In the field of adult stem cells, mesenchymal stem cells (MSCs) have become the most extensively studied and clinically explored stem cell type due to their wide sources (umbilical cord, placenta, adipose tissue, bone marrow, etc.), low immunogenicity, and multi-directional differentiation potential. In recent years, researchers have achieved efficient amplification and purity improvement of MSCs by optimizing the isolation and culture system. At the same time, gene modification technology has been used to enhance their paracrine function, significantly improving their anti-inflammatory, anti apoptotic, and vascular regeneration abilities in tissue repair. In addition, research breakthroughs in hematopoietic stem cells (HSCs) have focused on optimizing transplant matching and gene editing modifications. CRISPR-Cas9 technology has been used to modify the pathogenic genes in HSCs, and clinical efficacy has been achieved in the treatment of hereditary blood diseases such as sickle cell anemia and thalassemia.

Induced pluripotent stem cells (iPSCs) have made significant progress in improving reprogramming efficiency and controlling tumorigenic risk as an important alternative cell type to avoid ethical controversies surrounding embryonic stem cells in recent years. Researchers have significantly improved the induction efficiency of iPSCs and reduced the risk of genome integration by optimizing the combination of reprogramming factors and introducing small molecule compounds to regulate the epigenetic state of cells. More importantly, through the optimization of directed differentiation technology, iPSCs can efficiently differentiate into various functional cells such as cardiomyocytes, neurons, and pancreatic beta cells, providing an ideal cell source for personalized regenerative medicine treatment. In the field of embryonic stem cells, despite ethical controversies, related basic research continues to advance. Researchers have provided theoretical support for the functional regulation of other types of stem cells by analyzing the molecular regulatory network that maintains the pluripotency of embryonic stem cells. At the same time, the construction of embryonic stem cell-derived organoids has provided important tools for disease modeling and drug screening.

2.2 Key technology innovation and application exploration

The clinical translation of stem cell technology relies on innovative breakthroughs in key supporting technologies. In recent years, the development of directed differentiation technology, cell delivery systems, and interdisciplinary fusion technology has significantly improved the safety and effectiveness of stem cell therapy. In terms of directed differentiation technology, researchers have achieved precise directed differentiation of stem cells into specific functional cells by analyzing the signaling pathway regulation mechanisms of stem cell differentiation (such as Wnt, Notch, Hedgehog, etc.), using small molecule compounds, cytokine combinations, and gene regulation. For example, by regulating signaling pathways such as BMP and TGF - β, MSCs can be efficiently induced to differentiate into chondrocytes and osteoblasts, providing a cellular source for the repair of motor system injuries; By optimizing the composition of neural induction culture medium, efficient differentiation of iPSCs into mature neurons can be achieved, laying the foundation for the treatment of neurodegenerative diseases.

In terms of innovation in cell delivery systems, traditional intravenous or local injection methods have problems such as low cell survival rates and poor homing efficiency. In recent years, stem cell delivery systems based on biomaterials have become a research hotspot. Researchers have used 3D bioprinting technology to construct biomimetic scaffolds, combining stem cells with biocompatible materials such as collagen, sodium alginate, polylactic acid, etc., to achieve precise localization,

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

delivery, and controlled release of stem cells. At the same time, the scaffold material can provide a good microenvironment for cell growth, significantly improving the survival rate of cell colonization. In addition, extracellular vesicles (especially exosomes), as the core carrier of stem cell paracrine function, have been developed into cell-free therapy products in recent years. They have the advantages of low immunogenicity and easy storage and transportation, effectively avoiding the tumorigenic risk of stem cell transplantation. Preclinical research has been carried out in the fields of inflammatory diseases, tissue damage repair, etc.

2.3 Research on regenerative repair in major disease fields

Stem cell technology has shown significant potential in regenerative repair research in multiple disease fields, providing a new approach for clinical treatment. In the field of cardiovascular disease, stem cell therapy has become an important research direction for diseases such as myocardial infarction and heart failure. By delivering MSC or iPSC derived cardiomyocytes to damaged myocardial sites, replacement and repair of cardiomyocytes can be achieved, while promoting vascular regeneration through paracrine effects, improving the myocardial microenvironment, and enhancing cardiac function. Preclinical studies have shown that stem cell delivery systems combined with biological scaffolds can significantly improve myocardial repair efficacy, and relevant clinical trials have entered phase II.

In the field of neurodegenerative diseases, stem cell therapy brings new hope for the treatment of diseases such as Parkinson's disease and Alzheimer's disease. Researchers supplement functional cells in damaged brain tissue by transplanting neural stem cells or iPSC derived dopaminergic neurons, while also protecting residual neurons and delaying disease progression by paracrine neurotrophic factors. In the field of digestive system diseases, the combined application of liver stem cells and mesenchymal stem cells has made progress in the repair research of cirrhosis, by promoting liver cell regeneration, inhibiting liver fibrosis process, and improving liver function. In addition, the research of stem cell technology in sports system diseases (articular cartilage injury, bone defect), diabetes (islet β cell regeneration), skin wound repair and other fields has also continued to advance. Several projects have entered the clinical research stage, showing a good application prospect.

3. Clinical translation status and case analysis of stem cell technology

3.1 Overall situation of global clinical translation of stem cells

The global clinical translation of stem cells has entered a stage of parallel exploration and standardized development. According to data from the clinical research registration platform, as of 2025, there are over 1200 registered stem cell clinical research projects worldwide, covering more than 20 therapeutic fields such as cardiovascular diseases, neurodegenerative diseases, and metabolic diseases. From a regional distribution perspective, the United States and the European Union, with their well-established regulatory systems and technological accumulation, occupy a leading position in clinical translation. The US Food and Drug Administration (FDA) has significantly shortened the review cycle of innovative stem cell products through the "Advanced Therapy for Regenerative Medicine" (RMAT) acceleration channel. The European Union, relying on the "Horizon 2020" plan, has built a cross-border collaborative clinical translation network to promote breakthroughs in the application of stem cell therapy in the field of rare diseases.

The clinical transformation system of stem cells in China has been gradually improved. Since the introduction of the Administrative Measures for Clinical Research on Stem Cells (Trial) and other policies, more than 100 clinical research projects have been recorded and carried out, covering key disease fields such as diabetes, cirrhosis and spinal cord injury. Especially in the fields of pancreatic islet regeneration and nerve repair, local research teams have achieved internationally influential transformation results, and some products have entered the critical stage of clinical trials, marking a leap from following to running and crossing in the clinical transformation of stem cells in China. In addition, the trend of global regulatory coordination is becoming increasingly evident, and major economies such as China, the United States, and Europe are promoting mutual recognition of quality standards for stem cell products, laying the foundation for cross-border technology transformation.

3.2 Analysis of typical clinical conversion cases

In the field of metabolic diseases, stem cell derived islet transplantation has become a breakthrough

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

in the treatment of diabetes. The team from Shanghai Changzheng Hospital, in collaboration with the Chinese Academy of Sciences, has developed the "allogeneic human regenerated pancreatic islet injection (E-islet 01)", which uses directed differentiation technology of endodermal stem cells to prepare functional pancreatic islets. After minimally invasive infusion through the hepatic portal vein, precise regulation of blood glucose can be achieved. Clinical research shows that this product has successfully achieved functional cure for patients with type 1 diabetes, and has avoided tumorigenic risks through standardized preparation technology. At present, it has obtained the implied permission of clinical trials from the State Food and Drug Administration, becoming the first allogeneic universal regenerative pancreatic island product approved clinically in China. At the same time, the team of Tianjin First Central Hospital used chemical reprogramming to induce pluripotent stem cells to prepare islet cells, and successfully completed the world's first clinical transplantation of type 1 diabetes. The patient has been free of insulin dependence for more than one year after surgery, which verifies the clinical value of personalized stem cell therapy.

In the field of immune related diseases, the translational application of mesenchymal stem cell (MSC) therapy has become mature. Multiple clinical trials worldwide have confirmed that umbilical cord blood derived MSCs can significantly reduce the incidence of graft-versus-host disease (GVHD) through immunomodulatory effects, especially in severely steroid resistant GVHD patients, with an effective rate of over 60%. The success of such cases has promoted MSC therapy as an important treatment for complications after blood system transplantation, and also provided a reference paradigm for the treatment of other autoimmune diseases.

3.3 Core links and quality control in clinical translation

The standardized preparation of stem cell preparations is a core prerequisite for clinical translation. According to the "Guidelines for Quality Control and Preclinical Research of Stem Cell Preparations (Trial)", a two-level management system of main cell bank and working cell bank should be established for clinical use of stem cells, strictly controlling the compliance and traceability of cell sources, and ensuring the uniformity of preparation quality through full process inspections such as cell viability testing, microbial contamination screening, phenotype identification, etc. In terms of preparation process, the standardized operation of GMP cleanrooms, the application of serum-free culture media, and the optimization of large-scale amplification technology have become key technological paths to reduce formulation costs and ensure clinical safety.

The optimization of cell delivery systems and clinical efficacy evaluation constitute another core aspect of quality control. Personalized delivery methods need to be matched for different disease scenarios, such as local injection using stents for cardiovascular diseases, and precise implantation using stereotactic technology for neurological diseases. At the same time, establishing an evaluation system that includes short-term adverse reaction monitoring and long-term efficacy tracking, combined with biomarkers such as blood glucose fluctuations and immune indicators, can achieve dynamic control of treatment efficacy. In addition, the construction of interdisciplinary collaboration mechanisms is also crucial. Only by integrating technologies from multiple fields such as stem cell engineering, transplant surgery, and endocrinology can efficient translation from laboratory to clinical be achieved.

4. Challenges faced by clinical translation of stem cell technology

4.1 Core technical bottlenecks

The imperfect technical system is the primary obstacle to the clinical translation of stem cells, which is mainly reflected in the three core aspects of standardized preparation, safety assurance, and delivery efficiency. In terms of standardized preparation, the heterogeneity of stem cell sources is prominent. Stem cells from different donors and tissue sources have significant differences in activity, differentiation potential, and paracrine function. However, there is currently a lack of unified separation, culture, and expansion technology specifications, which makes it difficult to standardize the quality of stem cell preparations prepared by different institutions. According to statistics, the review data from the National Medical Products Administration shows that 37% of stem cell application projects were returned due to non-standard preparation processes, reflecting the urgency of standardization construction. At the same time, the technology for large-scale preparation of stem cells is not yet mature, and the popularity of closed and automated culture systems is low, which makes it difficult to

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

meet the needs of clinical batch applications. Moreover, the high preparation cost further limits the accessibility of the technology.

Security risk management remains the core difficulty of technological breakthroughs. Although third-generation induced pluripotent stem cells (iPSCs) have reduced the risk of genomic mutations through non integrated reprogramming techniques, the tumorigenic risk caused by residual undifferentiated cells has not been completely eliminated. Long term follow-up data shows that ectopic tissue growth has occurred in a few clinical trials. In addition, although the immune rejection reaction after stem cell transplantation is alleviated through the construction of HLA homologous donor libraries, it may still cause immune imbalance in complex disease microenvironments, affecting treatment efficacy. In the process of cell delivery, traditional infusion methods suffer from low homing efficiency of stem cells and a survival rate of less than 30% at the site of injury. The balance between the biocompatibility, degradation rate, and cell activity guarantee of targeted delivery systems has not yet been optimally regulated, which restricts the full potential of therapeutic effects.

4.2 Ethical and regulatory challenges

Ethical disputes and the lagging regulatory system constitute important institutional barriers to the clinical translation of stem cells. At the ethical level, research on embryonic stem cells has always faced controversies at the boundary of bioethics due to its involvement in the acquisition and use of human embryos. The ethical acceptance varies greatly among different countries, which limits the cross-border collaborative research of related technologies. At the same time, the application of gene editing technology in stem cell modification may lead to ethical risks such as off target genes and reproductive cell editing. How to establish ethical red lines for the application of technology has become a global consensus problem. In addition, the informed consent mechanism for stem cell therapy is not yet perfect, and patients have asymmetric perceptions of technical risks and efficacy expectations, which may lead to medical ethical disputes.

The inadequate adaptability of the regulatory system further hinders the conversion process. As a "live drug", stem cells are far more complex than traditional drugs, but the current regulatory framework still has problems such as unclear classification management and unclear approval paths. The "dual track" management model implemented in China, while balancing clinical research and application exploration, has also led to regulatory arbitrage in some institutions, disrupting industry order. At the international level, the regulatory standards of major economies such as China, the United States, and Europe are not unified. For example, there are differences between the RMAT acceleration channel of the US FDA and China's priority review mechanism, which increases the difficulty of cross-border transformation of stem cell products. At the same time, regulatory techniques are relatively outdated, and there is a lack of efficient tools for quality traceability and dynamic monitoring of clinical efficacy of stem cell preparations, making it difficult to achieve full chain risk control.

4.3 Social cognition and industry level challenges

Social cognitive bias and trust crisis have constrained the clinical promotion of stem cell technology. Some institutions, in pursuit of commercial interests, excessively promote the efficacy of stem cell therapy and even exaggerate the scope of treatment, leading to the spread of the misconception of a "panacea". Once there are cases of treatment failure, it is easy to trigger social trust and questioning of the entire industry. At the same time, the public lacks a comprehensive understanding of the scientific principles and potential risks of stem cell technology, coupled with the amplification effect of negative events in the industry, which further exacerbates cognitive biases and affects patients' enthusiasm for participating in clinical trials.

The imperfect industrial ecology is the core barrier to technological industrialization. In the upstream of the industrial chain, the quality control system for cell storage and raw material supply is not yet sound; There is a disconnect between basic research and clinical needs in the midstream R&D process, with about 85% of basic research results unable to be converted into applied technologies due to a lack of clinical guidance; The downstream commercialization path is unclear, and the cost of stem cell therapy generally exceeds 100000 yuan, which is not included in the medical insurance reimbursement system, resulting in high payment pressure for patients. In addition, there are structural flaws in the investment and financing mechanism, with social capital mostly focused on late stage clinical trial projects and insufficient funding support for early to mid stage basic research, leading to the breakage of the technology transformation chain. At the same time, the collaborative

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

commercialization model of "hospital+enterprise+insurance" is not yet mature, and the industrial cluster effect is not obvious, making it difficult to form advantages for large-scale development.

5. Development trends and prospects of stem cell technology in regenerative medicine

5.1 Technological development trends

The development of stem cell technology presents three core trends: precision, multi technology integration, and cell-free. In terms of precision development, personalized customization of induced pluripotent stem cells (iPSCs) and deep integration of gene editing technology have become key directions. By using gene editing tools such as CRISPR-Cas9 to correct pathogenic genes in stem cells, precise preparation of "patient adapted" cell preparations can be achieved, significantly improving the targeting and safety of treatment. Meanwhile, the construction of a cell function prediction model based on single-cell sequencing and AI technology can accurately screen high activity and low-risk stem cell subpopulations, providing high-quality cell sources for clinical treatment.

The integration of multiple technologies is an important path to enhance the efficacy of stem cell therapy, and the collaborative innovation between stem cell technology, 3D bioprinting, and biomaterial engineering is particularly prominent. For example, the development of iPSC derived myocardial cell flexible patches uses 3D printing technology to construct cell carriers that are compatible with human tissues, achieving precise delivery and functional integration under minimally invasive conditions, and solving the problem of low homing efficiency in traditional infusion methods. In addition, the combination of stem cell and organoid technology not only provides efficient tools for disease modeling and drug screening, but also lays the technical foundation for the regeneration and repair of complex tissues and organs. The rise of cell-free therapy technology has become an important exploration direction to avoid tumorigenic risks. Extracellular vesicles, cytokines and other bioactive substances derived from stem cells, with their low immunogenicity and easy storage and transportation advantages, have shown great potential for application in inflammation regulation and tissue repair.

5.2 Clinical translational prospects

In the next 5-10 years, stem cell technology will achieve breakthrough progress in clinical translation in multiple disease fields, forming an upgraded treatment model from "symptom relief" to "root cause cure". In the field of neurodegenerative diseases, iPS cell-derived dopaminergic neuron therapy has achieved 12 months of long-term positive data in the treatment of Parkinson's disease. With technological optimization, it is expected to become the standard treatment for such diseases. In the field of metabolic diseases, the promotion of clinical trials of allogeneic universal regenerative islet products will effectively solve the problem of the shortage of traditional islet transplantation donors, and bring functional cure possibilities to patients with type 1 and severe type 2 diabetes.

In the field of sports system diseases and cardiovascular diseases, the repair scheme of mesenchymal stem cells combined with biological scaffolds has entered phase III clinical trials, which is expected to achieve precise repair of joint cartilage injury and myocardial infarction. In addition, the potential of stem cell technology in the field of rare disease treatment will be further unleashed, providing new treatment options for rare disease patients who lack effective treatment plans through targeted cell replacement and functional reconstruction. With the continuous accumulation of clinical data and the maturity of technology, stem cell therapy will gradually be incorporated into the conventional medical system, achieving a transformation from "niche exploration" to "accessible to the public".

5.3 Policy and industrial development suggestions

At the policy level, it is necessary to further improve the standardized supervision and innovation incentive system. We should accelerate the legislative process of the "Regulations on the Administration of Clinical Research and Clinical Translational Applications of Biomedical New Technologies", clarify the regulatory boundaries and transformation paths of stem cell technology, optimize the "priority review and approval" channel, include clinically urgently needed stem cell products in the scope of rapid review, and shorten the transformation cycle. At the same time, establish a cross regional mechanism for mutual recognition of quality standards, promote regulatory coordination among major economies such as China, the United States, and Europe, and reduce

ISSN 2616-5791 Vol. 7, Issue 1: 33-39, DOI: 10.25236/AJMHS.2026.070105

cross-border conversion costs.

Industrial development requires the construction of an integrated and collaborative ecosystem of "industry university research application". Upstream should strengthen the standardization and control of stem cell raw materials, promote GMP level closed and automated cultivation systems, and reduce preparation costs; The midstream needs to strengthen the connection between basic research and clinical needs, focus on the layout of core technology research and development in major disease areas, and improve the efficiency of achievement transformation; Downstream should explore the commercialization model of "hospital+enterprise+insurance", promote the inclusion of stem cell therapy in the medical insurance payment system, and alleviate the payment pressure on patients. In addition, we should rely on pilot platforms such as the Guangdong Hong Kong Macao Greater Bay Area to carry out stem cell technology innovation pilot projects, cultivate industrial clusters, and activate the billion dollar regenerative medicine industry market through policy empowerment and capital guidance.

6. Conclusion

This article systematically reviews the research progress and clinical translation status of stem cell technology in the field of regenerative medicine, deeply analyzes the core challenges in the transformation process, and looks forward to future development trends. Research has shown that stem cell technology, with its unique self-renewal and multidirectional differentiation characteristics, has become a core driving force for the development of regenerative medicine. Different types of stem cells exhibit differentiated advantages in clinical translation: mesenchymal stem cells have matured in immune regulation and tissue repair, inducing pluripotent stem cells to provide an ideal cell source for personalized therapy, and embryonic stem cells provide important theoretical support for basic research. The innovative integration of key technologies, especially breakthroughs in directed differentiation, 3D bioprinting, and cell-free therapy, has further solidified the technological foundation for clinical translation. Clinical trials in neurodegenerative diseases, metabolic diseases, and other fields have achieved phased results.

At the same time, research has confirmed that the clinical translation of stem cell technology still faces multiple bottlenecks, including insufficient standardized preparation and safety risks at the technical level, institutional compatibility issues at the ethical regulatory level, and a broken transformation chain at the industrial level, which collectively constrain the large-scale application of technology. In the future, stem cell technology needs to develop towards precision and multi technology integration, and improve the transformation system through collaborative innovation of "industry university research application".

In summary, stem cell technology has irreplaceable application value and broad development prospects in the field of regenerative medicine. Promoting technological innovation and regulatory standards in parallel, and linking basic research with clinical needs, is a key path to breaking through barriers to transformation and realizing the industrialization of technology. It will provide revolutionary solutions for the treatment of difficult diseases and help promote high-quality development in the field of regenerative medicine.

References

[1] Wang C, Zhan Q Y. Current Status and Prospects of Regenerative Medicine Development [J]. Chinese Journal of Tuberculosis and Respiratory Medicine, 2020, 43 (1): 3-6.
[2] Zhou Q, Pei D Q. Opportunities and challenges for the development of stem cell research and regenerative medicine [J]. Chinese Science: Life Sciences, 2021, 51 (5): 561-574.
[3] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4): 663-676.
[4] Nair S, Mezey E. Mesenchymal stem cells: mechanisms of inflammation modulation[J]. Cellular and Molecular Life Sciences, 2009, 66(10): 1631-1648.
[5] Li L J, Zheng S S. Ethical and regulatory considerations for clinical translation of stem cells [J]. Chinese Journal of Medicine, 2019, 99 (3): 161-163.